Is Cogent Biosciences, Inc. (COGT) a Buy, Sell, or Hold?
NASDAQ : COGT
Cogent Biosciences, Inc.
$38.93 USD
-$2.43 (-5.88%)
- Volume
- 1.52M
- Average Volume
- 2.45M
- Market Capitalization
- $6.65B
- P/E Ratio
- -12.64
- Dividend Yield
- 0.00%
- Price Target
- $48.50
- Year High
- $43.73
- Year Low
- $10.38
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $15.14
Company Overview
NASDAQ
Andrew R. Robbins
Biotechnology
Healthcare
COGT
258
US
USD
Liquidity Metrics
0.39
15.14
15.14
4.16
0.00
Sales & Valuation
-$
0.00
4.32
-23.24
-4.25
Profitability
-$2.55
-$328.94M
0.00%
0.00%
-83.29%
-39.24%
P/E Metrics
-12.64
0.47
0.47
Analyst Price Target & Rating
$48.50
$55.00
$35.00
1/5
12 Analysts
-19.73%
Financial Health Scores
11.41
3/9
$819.82M
$903.01M
$295.31M
-$354.57M
Key Metrics (TTM)
$6.65B
0.00
-18.97
15.14
-83.29%
-42.77%
-13.50%
-4.30%
-1438 days
Company Executives
| Name | Title |
|---|---|
| Brad Barnett | Chief Technology Officer |
| Abb Hayden | Senior Vice President of Sales |
| John Edward Robinson | Chief Scientific Officer |
| Andrew R. Robbins | President, Chief Executive Officer & Director |
| Christi Waarich | Senior Director of Investor Relations |
| Jessica Sachs | Chief Medical Officer |
| Cole Pinnow | Chief Commercial Officer |
| Evan D. Kearns | Chief Legal Officer & Corporate Secretary |
| John L. Green | Chief Financial Officer & Principal Accounting Officer |
| Erin Schellhammer | Chief People Officer |
Poll Results
No votes yet today — be the first to share your view!
About Cogent Biosciences, Inc. (NASDAQ:COGT) Stock
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massac ... husetts.
2026-06-30 08:00:00
Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated safety profile for AdvSM patients
Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage
2026-06-14 09:13:38
Cogent Biosciences is positioned to build a niche KIT-mutant franchise, leveraging bezuclastinib across three pivotal indications with strong clinical data. COGT holds $866.4 million in cash, supporting operations through 2028 and enabling launches in systemic mastocytosis and GIST, mitigating near-term financing risk. Bezuclastinib has demonstrated robust efficacy in nonadvanced and advanced systemic mastocytosis and second-line GIST, with three regulatory filings and positive pivotal trial results.
2026-06-12 08:01:00
- JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors -
2026-06-12 08:00:00
-- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria –
2026-05-30 08:00:00
Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16. 5 months versus 9. 2 months (HR=0. 50, CI: 0. 39-0.
2026-05-30 08:00:00
Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50, CI: 0.39-0.65, p
2026-05-28 08:00:00
NDA acceptance with Priority Review builds upon previous assignment of Breakthrough Therapy Designation and Real-Time Oncology Review following Phase 3 PEAK results; PDUFA date set for November 30, 2026
Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference
2026-05-27 08:00:00
WALTHAM, Mass. and BOULDER, Colo.
Frequently Asked Questions
-
What is the current Cogent Biosciences, Inc. (COGT) stock price?
-
Cogent Biosciences, Inc.(NASDAQ:COGT) stock price is $38.93 in the last trading session. During the trading session, COGT stock reached the peak price of $43.73 while $10.38 was the lowest point it dropped to. The percentage change in COGT stock occurred in the recent session was --5.88% while the dollar amount for the price change in COGT stock was -$2.43.
-
COGT's industry and sector of operation?
-
The NASDAQ listed COGT is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of COGT?
-
Brad Barnett | Chief Technology Officer
Abb Hayden | Senior Vice President of Sales
John Edward Robinson | Chief Scientific Officer
Andrew R. Robbins | President, Chief Executive Officer & Director
Christi Waarich | Senior Director of Investor Relations -
How many employees does COGT have?
-
Number of COGT employees currently stands at 258. COGT operates from 200 Cambridge Park Drive, Waltham, MA 02140, US.
-
Link for COGT official website?
-
Official Website of COGT is: https://www.cogentbio.com
-
How do I contact COGT?
-
COGT could be contacted at phone #617 945 5576 and can also be accessed through its website. COGT operates from 200 Cambridge Park Drive, Waltham, MA 02140, US.
-
How many shares of COGT are traded daily?
-
The average number of COGT shares traded daily for last 3 months was 2.45M.
-
What is the market cap of COGT currently?
-
The market value of COGT currently stands at $6.65B with its latest stock price at $38.93